EU drops antitrust probe as Edwards Lifesciences ends anti-copycat policy
EU regulators closed their probe into Edwards Lifesciences after the firm scrapped an anti-copycat policy. The move follows a complaint from Indian rival Meril.
Insights:
The European Commission has officially closed its antitrust investigation into Edwards Lifesciences Corporation following the company's decision to withdraw its Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP). Announced on February 16, 2026, the closure comes after the Commission concluded that the policy's withdrawal addressed the competition concerns that had prompted the inquiry. By rescinding the policy, the firm, which is headquartered in the United States 
US, has successfully removed the immediate regulatory overhang and the risk of substantial antitrust fines.
US, has successfully removed the immediate regulatory overhang and the risk of substantial antitrust fines.The investigation into the medical technology provider was initiated after a formal complaint from Meril, a competitor based in India 
IN. Regulatory interest intensified in September 2023 when officials conducted a raid on the company's facilities. The probe was centered on whether the Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP) had been used to stifle competition. However, with the policy now withdrawn, the European Commission stated that further action at the European Union level is no longer a priority.
IN. Regulatory interest intensified in September 2023 when officials conducted a raid on the company's facilities. The probe was centered on whether the Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP) had been used to stifle competition. However, with the policy now withdrawn, the European Commission stated that further action at the European Union level is no longer a priority.
